Online inquiry

IVTScrip™ mRNA-Anti-IL3RA, DT-IL-3(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ6842MR)

This product GTTS-WQ6842MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets IL3RA gene. The antibody can be applied in Chronic lymphocytic leukemia (CLL) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_001267713.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3563
UniProt ID P26951
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL3RA, DT-IL-3(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ6842MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ10765MR IVTScrip™ mRNA-Anti-FGFR4, M-70(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA M-70
GTTS-WQ3088MR IVTScrip™ mRNA-Anti-FASLG, APG-101(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA APG-101
GTTS-WQ13266MR IVTScrip™ mRNA-Anti-MSTN, PF-06252616(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA PF-06252616
GTTS-WQ11815MR IVTScrip™ mRNA-Anti-PDCD1, MK-3475(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA MK-3475
GTTS-WQ14336MR IVTScrip™ mRNA-Anti-EGFL7, RG7414(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA RG7414
GTTS-WQ4342MR IVTScrip™ mRNA-Anti-IL5RA, BIW-8405(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA BIW-8405
GTTS-WQ5619MR IVTScrip™ mRNA-Anti-KDR, CDP791(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA CDP791
GTTS-WQ14740MR IVTScrip™ mRNA-Anti-CD19, SGN-19A(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA SGN-19A
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW